Background: Although mutations in the interferon (IFN) sensitivity determining region (ISDR) of hepatitis C virus (HCV) have been reported to be useful as a predictive viral factor for IFN therapy in patients infected with HCV-1b, such laboratory research has not been favorably translated into the clinic. To promote such translation, we attempted the establishment of a rapid and simple polymerase chain reaction (PCR) combined with melting curve analysis (MCA) to screen for mutations in the ISDR and for the monitoring of HCV quasispecies. Methods: A PCR-MCA protocol was established using in-house primers and hybridization probes designed according to the results of direct sequencing of 34 HCV-1b samples. Then, the performance of PCR-MCA was verified by comparing with mutation profiles obtained by direct sequencing and sequencing after cloning. Results: The MCA assay revealed that melting temperature (Tm) was inversely correlated with the number of nucleotide (nt) and amino acid substitutions in the ISDR deduced on the basis of the results of direct sequencing. A boundary Tm of 58.08C allowed us to discriminate HCV genomes into two groups: one with a Tm )58.08C had no or a low number of nt substitutions, while the other genomes with a Tm -58.08C had a high number of nt substitutions, corresponding to wild-type in the former and mutant-type in the latter in respect of a clinical setting for IFN therapy. Moreover, this MCA assay provided precise discrimination of Tm between clones, reflecting the degree of the genetic complexity of HCV genomes. Conclusions: This study indicates that the MCA assay is useful to rapidly and simply screen the mutational
Introduction
The hepatitis C virus (HCV) is an RNA virus belonging to the Flaviviridae. It has a single strand and a genome of approximately 9.6 kb with a single open reading frame encoding four structural (C, E1, E2, and p7) and six non-structural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins (1) . HCV is persistently present in plasma as a mixture of heterogeneous HCV RNA genomes, quasispecies, and causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) in humans. Patients with HCC have been reported to be prevalent in the Nagasaki district and a majority of them are seropositive for the virus (2) . Fortunately, recent advances in the treatment of chronic hepatitis C are promising, namely interferon-ribavirin combination therapy, as the mainstay treatment for chronic hepatitis C. However, such combination therapy is not always effective in all patients with HCV-related disorders and can also cause adverse events associated with the drugs (3, 4) . Since recently, the HCV core antigen has been generally used to quantitatively monitor HCV viremia, but is not appropriate for monitoring the complexity of the HCV genome relating to HCV quasispecies. For these reasons, a biomarker to predict the efficacy of interferon (IFN) therapy is required. At present, the presence of the HCV genotype-2 or -3 and a low viral load prior to treatment have been proposed and applied in a practical setting as predictive markers for the effectiveness of IFN therapy (5) . Although HCV genotype 1b is resistant to IFN therapy, Enomoto et al. (6) reported that mutations in the interferon sensitivity determining region (ISDR) within the NS5A gene are useful as predictive markers of the response to IFN therapy for chronic hepatitis patients with a Japan-specific subtype (J-type) of the HCV genotype 1b. The ISDR corresponding to codons 2209-2248 of the HCV genome (NS5A2209- 2248) can interact with the double-strand RNA protein kinase. This interaction has been shown to be able to block the IFN signaling pathway, leading to HCV resistance to IFN therapy (7, 8) . However, the precise mechanism of IFN resistance remains unresolved, because the regions other than ISDR, such as E2, NS3/ 4, and NS5A, have also been reported to be involved in resistance to IFN therapy in Japanese patients (9, 10) . Mutations in the ISDR that are expected to be useful as predictive markers have not yet been introduced into the clinical setting. One of the reasons is that the methodology used for routine laboratory tests is inapplicable because it is labor-, time-, and costconsuming.
In the present study, to evaluate the implications of nucleotide substitutions within the ISDR in the resistance to IFN therapy and in quasispecies, we examined the genetic heterogeneity in the ISDR of HCV isolates from clinical samples. Then, we attempted to develop a rapid and easy methodology for screening of nucleotide mutations using polymerase chain reaction (PCR) combined with melting curve analysis (MCA).
Materials and methods

Study samples
HCV samples were collected from plasma specimens from patients admitted to our hospital. Clinical information was referred from the hospital information system, as summarized in Table 1 . HCV genotyping was determined with multiplex PCR, as described by Ohno et al. (11) . Quantitation of serum HCV RNA and HCV antigens was performed according to the manufacturer's instructions using a commercial kit (Ortho HCV Antigen IRMA Test, Ortho Clinical Diagnostics, Raritan, NJ, USA). HCV isolates with genotype type-1b classified according to the typing system by Ohno et al. (11) were enrolled in the study. Clinical virological assay for the qualification and quantitation was carried out using commercial assay kits (AMPLICORE HCV Monitor test, version 2.0 and AMPLICORE HCV, version 2.0, Roche Diagnostics, Basel, Switzerland).
HCV RNA extraction, amplification by nested PCR, and sequencing
HCV RNA was extracted from serum samples using a QIAamp Viral RNA Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions. (59labeled LCRed640) 59-CGACATGTACTACCCATCATGACT-39-P cDNA was generated using SuperScript III Reverse Transcriptase (Invitrogen Corp., Carlsbad, CA, USA) and antisense primer or random hexamer oligonucleotides. A fragment of 251 bp including the ISDR was amplified by nested PCR using primers, as described previously (12) . The amplicons were subjected to single strand conformation polymorphism (SSCP) and direct sequencing analysis to identify mutations in the ISDR. PCR-SSCP was performed according to the standard method (13, 14) . Direct sequencing was carried out with a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) using an Automated DNA Sequence Analyzer (Model 310, Applied Biosystems). The nucleotide (nt) and deduced amino acid (aa) sequences of the ISDR were aligned and compared with that of the HCV-J prototype (15) . From several samples, PCR products were cloned using a DynaExpress TA PCR Cloning Kit with Jet Competent Cells (BioDynamics Laboratory Inc., Tokyo, Japan) and then each clone was sequenced and subjected to the MCA assay.
PCR-MCA
To screen for mutations in the PCR amplified products in the ISDR, MCA analysis was applied using a LightCycler instrument equipped with the DNA MCA analysis program (LightCycler Software Version 3.0) (16) . Briefly, reactions
were performed in a 20-mL volume with 5 mM MgCl 2 , 2 mL 1/10,000 diluted PCR product, 0.5 mM PCR primers, 0.4 mM anchor and sensor hybridization probes ( 
Results
Mutation in the ISDR and relevancy for probe setting
To evaluate the heterogeneity of mutations in the ISDR (nts 6954-7073), a fragment of the region was amplified and sequenced directly for 34 HCV samples. Compared with a reference sequence of the HCV-1b prototype (Gene Bank accession D90208), the sites of nt substitutions were mainly distributed in two regions at or near nt 6974 and nt 7070, as shown in Figure 1 . Although the site of silent mutations (open columns) was widely distributed, the site of missense mutations (solid columns) was concentrated to the region of nts 6960-6990 corresponding to codons 2211-2221. The number of aa substitutions corresponding to missense mutations was from 0 to 6, with no substitution (wild-type) in 15 cases, one in nine cases, and two or more in 10 cases. As all cases had at least one nt substitution with concentration of missense mutations within the region of nts 6954-6990, the probe site was targeted in the region, as shown in Table 2 . The G:C content of the anchor probe was approximately 53.9%, and sensor probe was 46.7%. Using this probe, our PCR-MCA method yielded reasonably sharp melting curves in all 34 cases with total 
Performance of PCR with MCA discriminating heterogeneity in the ISDR
As the Tm value is essentially regulated by heteroduplex formation depending upon various genetic and epigenetic alterations, we verified whether PCR with MCA can discriminate and screen the mutation status in the ISDR. As shown in Figure 2A , Tm values of amplicons derived from blood samples varied from approximately 458C to 658C, and were inversely correlated with the number of nt substitutions (rsy0.689, p-0.01) and the deduced aa substitution number (rsy0.617, p-0.01). In particular, Figure 2B reveals that the boundary of a Tm of 58.08C makes it possible to distinguish two major groups: a high Tm group of )58.08C and a low Tm group of -58.08C. Samples distributed in the high Tm area had mainly no or rarely one aa substitution, whereas samples distributed in the low Tm area had mainly two or more aa substitutions. However, although only samples having one aa substitution were distributed to both the high and low Tm areas, the total number of nt substitutions was different between them: approximately two times higher in samples distributed in the low Tm area rather than the high Tm area. Then, as shown in Table 3 , viral and clinical parameters between the high and low Tm groups were compared. The high Tm group showed a tendency of low nt and aa mutations, high viral load, and nonresponse to IFN. 1, 3, 4, 7, 8, 11, 12, 13, 14, 15, 18 , and 20. M, marker. 
HCV quasispecies and MCA
HCV is present in plasma as a mixture of heterogeneous RNA genomes relating to HCV quasispecies. First of all, we examined the genetic complexity of the ISDR of HCV genomes by SSCP analysis. PCR-SSCP analysis revealed 2-7 bands (mean 5 bands, as shown in Figure 4 ), indicating that there were variant clones with differences in the degree of complexity even at the pre-treatment stage. Then, from four cases in lanes 3 (patient no. 17), 12 (no. 28), 20 (no. 37), and 1 (no. 15), a total of 86 clones were established and subjected to MCA assay. As shown in Figures 5 and 6B, MCA gave instructive Tm distributions forming several clusters with minor separated clones. The differences in Tm values among the clones were correlated to the nt substitution number, indicating that HCV genomes are heterogeneous in the ISDR case by case. These findings on Tm for amplicons and clones and their cluster patterns are shown in Figure 5 . For example, in patient no. 17, although the Tm of the amplicon was 57.28C, the Tms of clones were variable in a range of 50.78C-66.28C distributing in two major clusters around 50.88C and 57.88C, one minor cluster, and scattered clones. The band number was 3. In patient no. 15, changes in the composition of clones defined by Tm were monitored during IFN therapy, as shown in Figure 6 . The Tm of three HCV samples collected at the three clinical points of pre-treatment, discontinuation, and re-treatment was almost the same, 61.28C, 60.78C, and 61.08C, respectively, whereas dot plot distribution profiles of Tm after cloning of each sample were subtly different in the range of 51.08C-63.48C, 55.38C-60.78C, and 51.68C-62.38C, respectively. Notably, among these clones with different Tm, clones with values less than 55.08C disappeared after treatment with IFN, and they appeared again at the time of re-treatment. The major clones with high Tm remained unchanged.
Discussion
In this study, we developed a simple and rapid PCR-MCA method for screening the genetic heterogeneity of the ISDR of HCV genomes, indicating that this MCA assay is applicable for clinical use as a predictive marker of IFN efficacy or monitoring of the emergence of new clones. This is meaningful, because approximately 2% of the human population worldwide are infected with and suffer from HCV-related disorders. At present, IFN therapy makes it possible to relieve symptoms caused by HCV, such as chronic hepatitis, cirrhosis, and HCC (17, 18) . However, the current combination therapy of IFN and ribavirin is not universally effective in patients with chronic hepatitis C, showing response rates of 90%-40% (19) . The difference in responsiveness is thought to be in part explained by viral load and the genetic heterogeneity of the HCV genome (5, 6, 20) . In particular, genotype 1 prevalent in Japan is known to be resistant to IFN. Enomoto et al. (6) describe a correlation between the number of mutations within a 40 aa sequence of the ISDR and the response to IFN therapy in genotype-1b infected patients. Thus, although the mechanism of IFN resistance is now being elucidated, the translation from research laboratory to clinical application is poor. The practical application of findings of ISDR mutations and IFN responsiveness is no exception. The reason why practical applications lag behind current research is due in part to technical and economic problems in translating clinical laboratory tests, with regard to time, labor, and cost. Although there are many methodologies for the detection of mutations, such as sequencing, SSCP, DHPLC, microarray technology, etc., we examined MCA combined with PCR amplification, because it is a simple and rapid method for screening of genetic alterations. MCA is based on the basis that the Tm of duplex DNA is dependent upon the length, sequence, G:C content, and Watson-Crick base pairing (21, 22) .
As the Tm value precisely reflects genetic alterations in the ISDR, a sequence region of nts 6954-6990 with high nt substitutions was selected as the anchor and sensor probe sites. All 34 cases had at least one nt substitution (either silent or missense mutation) in the probe sites and especially missense mutations were concentrated in this region. In other words, sequence status of the probe sites is expected to surrogate the genetic alterations of the entire sequence in the ISDR, accounting for the Tm values reflecting mutational status of the ISDR. This is actually the confirmed by this study. Thus, our PCR-MCA method with the hybridization probe gave promising results enabling us to subcategorize HCV genomes into two major groups: one group with a Tm )58.08C and the other with a Tm -58.08C from the viewpoint of IFN efficacy. Compared with sequence results, the former and the latter are approximately equivalent to cases with no aa substitutions and cases with two or more aa substitutions, respectively. However, cases having the one aa substitution defined by direct sequencing were distributed between both groups. We can interpret the meaning of this finding, because the Tm value is generated as a comprehensive result based on the total nt substitution number of missense and silent mutations. Accordingly, considering the features of the MCA assay, it is reasonable to designate the high Tm group as wild-type and the low Tm group as mutant-type in a clinical setting. This stratification by Tm, despite the small number of pilot cases, suggests its usefulness in predicting the efficacy of IFN therapy: non-responsive in the high Tm group and responsive in the low Tm group. However, we need a large-scale prospective clinical trial to verify the reliability of Tm as a predictive marker, because the validity of the MCA assay in a practical setting has been partially shown in this study.
Another important point of this MCA assay is to indicate that Tm values after cloning display the composition profiles of viral variants within HCV quasispecies more clearly than SSCP. HCV genomes in plasma are generally present as a mixture of heterogeneous genomes, designated quasispecies. To better understand the resistance mechanism against IFN, HCV quasispecies are interesting and instructive, because the pressure of IFN on virus replication could allow the generation and selection of new clones with IFN resistance. Generally, although HCV quasispecies are defined by sequencing or SSCP with targets in the HCV E2 region, 59NCR, etc. regions (23) , the methodology for quasispecies remains problematic, in terms of time and cost. Our study showed that the MCA assay can simultaneously and rapidly screen the degree of the genetic complexity of HCV according to the differences in Tm of the ISDR. To understand the composition of quasispecies precisely, it requires the analysis of a large number of clones. The MCA assay could easily and efficiently pick up a newly derived clone different from other major clones by comparison of Tm.
In conclusion, this study demonstrates that the MCA assay rapidly and simply provides Tm values reflecting the genetic heterogeneity in the ISDR of the HCV genome. According to the Tm status provided by this MCA assay, HCV genomes were classified into two types with high and low Tms, corresponding to wild-type ISDR and mutant-type ISDR from the viewpoint of IFN efficacy. Moreover, the MCA assay is convenient and useful to screen newly generated clones by the difference in Tm of the clone relating to the behavior of quasispecies.
